PNC Financial Services Group
RADX

PNC Financial Services Group’s Radiopharm Theranostics RADX Stock Holding History

PNC Financial Services Group’s Portfolio RADX Stock Details RADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.8K Buy
20,000
+4,000
+25% +$17.8K ﹤0.01% 3044
2026
Q1 		$68.8K Hold
16,000
– – ﹤0.01% 3029
2025
Q4 		$83.5K Hold
16,000
– – ﹤0.01% 2915
2025
Q3 		$88.3K Buy
16,000
+8,000
+100% +$41.9K ﹤0.01% 2893
2025
Q2 		$37.1K Buy
+8,000
New +$35.9K ﹤0.01% 3279

PNC Financial Services Group's RADX Position: Q2 2026 in Review

PNC Financial Services Group increased its Radiopharm Theranostics (RADX) stake by 25% in Q2 2026, buying an estimated $17.8K and bringing the position to 20,000 shares worth $83.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3044.

PNC Financial Services Group first reported a position in RADX in Q2 2025 and has held it in 5 quarters since. The position peaked at $88.3K in Q3 2025. 1 fund tracked by Wall St. Rank holds RADX as of Q2 2026.

  • PNC Financial Services Group held 20,000 shares of Radiopharm Theranostics worth $83.8K as of Q2 2026.
  • PNC Financial Services Group bought 4,000 Radiopharm Theranostics shares in Q2 2026, an estimated $17.8K.
  • Radiopharm Theranostics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #3044 holding.
  • PNC Financial Services Group first reported a position in Radiopharm Theranostics in Q2 2025 and has held it in 5 quarters since.
  • PNC Financial Services Group's Radiopharm Theranostics position peaked at $88.3K in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Radiopharm Theranostics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.